These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31125115)

  • 1. A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy.
    Strand SH; Bavafaye-Haghighi E; Kristensen H; Rasmussen AK; Hoyer S; Borre M; Mouritzen P; Besenbacher S; Orntoft TF; Sorensen KD
    Int J Cancer; 2019 Dec; 145(12):3445-3452. PubMed ID: 31125115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine.
    Fredsøe J; Rasmussen AKI; Mouritzen P; Borre M; Ørntoft T; Sørensen KD
    Int J Cancer; 2019 Nov; 145(9):2558-2567. PubMed ID: 30903800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
    Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
    Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
    Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
    Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.
    Haldrup C; Mundbjerg K; Vestergaard EM; Lamy P; Wild P; Schulz WA; Arsov C; Visakorpi T; Borre M; Høyer S; Orntoft TF; Sørensen KD
    J Clin Oncol; 2013 Sep; 31(26):3250-8. PubMed ID: 23918943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
    Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
    Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells.
    Laursen EB; Fredsøe J; Schmidt L; Strand SH; Kristensen H; Rasmussen AKI; Daugaard TF; Mouritzen P; Høyer S; Kristensen G; Stroomberg HV; Brasso K; Røder MA; Borre M; Sørensen KD
    Am J Pathol; 2019 Dec; 189(12):2377-2388. PubMed ID: 31539518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
    Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
    Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?
    Zhao Z; Stephan C; Weickmann S; Jung M; Kristiansen G; Jung K
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic predisposition to early recurrence in clinically localized prostate cancer.
    Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
    BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
    Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.
    Bian Z; Huang X; Chen Y; Meng J; Feng X; Zhang M; Zhang L; Zhou J; Liang C
    Int J Med Sci; 2021; 18(1):284-294. PubMed ID: 33390797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
    Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
    J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
    Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
    BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.
    Haddad BR; Erickson A; Udhane V; LaViolette PS; Rone JD; Kallajoki MA; See WA; Rannikko A; Mirtti T; Nevalainen MT
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1642-1651. PubMed ID: 31292140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
    Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology.
    Athanasiou A; Tennstedt P; Wittig A; Huber R; Straub O; Schiess R; Steuber T
    PLoS One; 2021; 16(11):e0259093. PubMed ID: 34767586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.